Headlines about Orthopediatrics (NASDAQ:KIDS) have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Orthopediatrics earned a coverage optimism score of 0.01 on Accern’s scale. Accern also assigned news articles about the company an impact score of 48.8260211959315 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of NASDAQ KIDS traded down $0.31 during midday trading on Friday, reaching $33.50. 46,823 shares of the stock were exchanged, compared to its average volume of 50,213. The company has a market cap of $432.44 million and a PE ratio of -5.88. Orthopediatrics has a 52-week low of $14.00 and a 52-week high of $35.50. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.98 and a quick ratio of 3.61.

Orthopediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Thursday, August 9th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). The firm had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.27 million. Orthopediatrics had a negative return on equity of 192.23% and a negative net margin of 61.99%. The company’s revenue was up 28.0% compared to the same quarter last year. analysts anticipate that Orthopediatrics will post -0.82 EPS for the current year.

A number of brokerages have issued reports on KIDS. Piper Jaffray Companies lifted their target price on shares of Orthopediatrics from $24.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, July 5th. BidaskClub upgraded shares of Orthopediatrics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 31st. Zacks Investment Research upgraded shares of Orthopediatrics from a “sell” rating to a “hold” rating in a research report on Friday, May 18th. ValuEngine upgraded shares of Orthopediatrics from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Finally, William Blair restated an “outperform” rating on shares of Orthopediatrics in a research report on Wednesday, June 27th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Orthopediatrics currently has an average rating of “Buy” and an average target price of $25.67.

In other news, General Counsel Daniel J. Gerritzen sold 9,525 shares of Orthopediatrics stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $33.73, for a total transaction of $321,278.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 46.10% of the company’s stock.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

Featured Article: How Short Selling Works

Insider Buying and Selling by Quarter for Orthopediatrics (NASDAQ:KIDS)

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.